Clinical and immunohistochemical prognostic factors in adult glioblastoma patients

Clinical Neuropathology

Volumn 28, Issue 5, 2009, Pages 362-372

  Umesh, S ^a   Tandon, A ^a   Santosh, Vani ^a   Anandh, B ^a   Sampath, S ^a   Chandramouli, B A ^a   Sastry Kolluri, V R ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

EGFR; Glioblastoma; Immunohistochemistry; KPS; P53; PTEN; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; EGFR PROTEIN, HUMAN; PTEN PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SURGICAL TECHNIQUE; SURVIVAL TIME; TREATMENT RESPONSE; AGE; BRAIN TUMOR; FOLLOW UP; HOSPITALIZATION; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEVERITY OF ILLNESS INDEX; SUPRATENTORIAL NEOPLASMS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 70350052877     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.2379/NPX08164     Document Type: Article

References (56)

1. Ammirati M, Vick N, Liao YL, Ciric I, Mikhael M. Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery. 1987; 21: 201-206.
2. Andersen AP. Postoperative irradiation of glioblastomas: results in a randomized series. Acta Radiol Oncol. 1978; 17: 475-484.
3. Backlund LM, Nilsson BR, Goike HM et al. Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN. Clin Cancer Res. 2003; 9: 4151-4158.
4. Baxendine-Jones J,Campbell I, Ellison D. p53 status has no prognostic significance in glioblastomas treated with radiotherapy. Clin Neuropathol. 1997; 16: 332-336.
5. Birner P, Piribauer M, Fischer I, Gatterbauer B, Marosi C, Ungersbock K et al. Prognostic relevance of p53 protein expression in glioblastoma. Oncology Reports 2002; 9: 703-707.
6. Branislav J, Biljana M, Danica G, Aleksandar D, Jasna A. Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach. J cancer res clin oncol. 2003; 129: 477-484.
7. Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol. 2003; 30: 10-14.
8. Burger PC, Green SB. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 1987; 59: 1617-1625.
9. Burton EC, Lamborn KR, Forsyth P, Scott J, O'Campo J, Uyehara-Lock J. Aberrant p53, mdm2, and Proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Canc Res. 2002; 8: 180-187.
10. Chandler KL, Prados M, Malec M, Wilson CB. Longterm survival in patients with glioblastoma multiforme. Neurosurgery 1993; 32: 716-720.
11. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie et al. Analysis of the phosphatidylinositol 3-kinase signaling pathway in glioblastoma patients in vivo. Canc Res. 2003; 63: 2742-2746.
12. Chozick BS, Pezzullo JC, Epstein MH, Finch PW. Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery 1994; 35: 831-837.
13. Cunningham JM, Kimmel DW, Scheithauer BW, O'Fallon JR, Novotny PJ, Jenkins RB. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. J Neurosurg. 1997; 86: 121-130.
14. Etienne MC, Formento JL, Lebrun-Frenay C, Gioanni J, Chatel M, Paquis P, Bernard C, Courdi A, Bensadoun RJ, Pignol JP, Francoual M, Grellier P, Frenay M, Milano G. Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. Clin Cancer Res. 1998; 4: 2383-2390.
15. Fine HA. The basis for current treatment recommendations for malignant gliomas. J Neuro-Oncol. 1994; 20: 111-120.
16. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M et al. Prognostic effect of epidermal growth factor receptor and egfrviii in glioblastoma multiforme patients. Clin Cancer Res. 2005; 11: 1462-1466.
17. Hurtt MR, Moossy J, Donovan-Peluso M, Locker J. Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J Neuropathol Exp Neurol. 1992; 51: 84-90.
18. Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM, Mendelow AD, Sengupta RP, Pearson AD. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer. 1992; 66: 373-385.
19. Kleihues P, Burger PC, Aldape KD et al. Glioblastoma. In: Louis DN, Ohgaki H, Weistler OD, Cavenee WK (eds).World Health Organisation Classification of Tumours: Pathology and Genetics of Tumors of the Nervous System. Lyon-France: IARC; 2007. p. 33-46.
20. Kleihues P, Burger PC, Collins VP, Newcomb EW, Ohgaki H, Cavenee WK. Glioblastoma. In: Kleihues P, Cavenee WK (eds). World Health Organisation Classification of Tumours: Pathology and Genetics of Tumors of the Nervous System. Lyon- France: IARC; 2000. p. 29-39.
21. Kleihues P, Ohgaki K. Primary and Secondary glioblastoma: from concept to clinical diagnosis. Neuro-oncology. 1999; 1: 44-51.
22. Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A, Stamoulis G, Seretis A, Thomas-Tsagli E. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer. 1997; 75: 1269-1278.
23. Kowalczuk A, Macdonald RL, Amidei C, Dohrmann G 3rd, Erickson RK, Hekmatpanah J. Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery. 1997; 41: 1028-1036.
24. Kristiansen K, Hagen S, Kollevold T, Torvik A, Holme I, Nesbakken R et al. Combined modality therapy of operated astrocytomas grade III and IV: confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981; 47: 649-652.
25. Kyritsis AP, Bondy ML, Hess KR, Cunningham JE, Zhu D, Amos CJ, Yung WK, Levin VA, Bruner JM. Prognostic significance of p53 immunoreactivity in patients with glioma. Clin Cancer Res. 1995; 1: 1617-1622.
26. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F et al. Amultivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001; 95: 190-198.
27. Lantos PL, VandenBerg SR, Kleihues P. Tumours of the nervous system. In: Graham DI, Lantos PL (eds). Greenfield's neuropathology. 6th ed. London: Arnold; 1997.
28. Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the glioma outcomes project. J Neurosurg. 2003; 99: 467-473.
29. Newcomb EW, Cohen H, Lee SR, Bhalla SK, Bloom J, Hayes RL, Miller DC. Survival of patients with glioblastoma multiforme is not influenced by altered expression of P16, P53, EGFR, MDM2 or Bcl-2 genes. Brain Pathology. 1998; 8: 655-667.
30. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL. Genetic Pathways to Glioblastoma. A Population-Based Study. Cancer Research. 2004; 64: 6892-6899.
31. Ohgaki H, Kleihues P. Genetic pathways to Primary and Secondary Glioblastoma. Am J Pathol. 2007; 170: 1445-1453.
32. Perren A, Komminoth P, Saremaslani P et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol. 2000; 157: 1097-1103.
33. Rainov NG, Dobberstein KU, Bahn H, Holzhausen HJ, Lautenschlager C, Heidecke V, Burkert W. Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neuro-oncol. 1997; 35: 13-28.
34. Rasheed BK, McLendon RE, Herndon JE, Friedman HS, Friedman AH, Bigner DD, Bigner SH. Alterations of the TP53 gene in human gliomas. Cancer Res. 1994; 54: 1324-1330.
35. Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS, Bigner DD, Bigner SH. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res. 1997; 57: 4187-4190.
36. Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, Rasheed BKA et al. Gene Expression Profiling and Genetic Markers in Glioblastoma Survival. Cancer Research. 2005; 65: 4051-4058.
37. Sandberg-Wollheim M, Malmstrom P, Stromblad LG, Anderson H, Borgstrom S, Brun A et al. A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer 1991; 68: 22-9.
38. Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML et al. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res. 1999; 59: 1820-1824.
39. Schmidt MC, Antweiler S, Urban N et al. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol. 2002; 61: 321-328.
40. Scott JN, Rewcastle NB, Brasher PM et al. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol. 1999; 46: 183-188.
41. Shapiro WR, Dean F, Young DF. Treatment of malignant glioma: a controlled study of chemotherapy and irradiation. Arch Neurol. 1976; 33: 494-500.
42. Shinojima N, Tada K, Shiraishi S et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme Cancer Res. 2003; 63: 6962-6970.
43. Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, Berger MS et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Research 2001; 61: 1122-1128.
44. Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys. 1993; 26: 239-244.
45. Smith JS, Tachibana I, Passe SM et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001; 93: 1246-1256.
46. Sneed P, Prados M, McDermott M, Larson D, Malec M, Lamborn K et al. Large effect of age on the survival of patients with glioblastoma treated with radiotherapy and brachytherapy boost. Neurosurgery. 1995; 36: 898-904.
47. Soini Y, Niemela A, Kamel D, Herva R, Bloigu R, Paakko P, Vahakangas K. p53 immunohistochemical positivity as a prognostic marker in intracranial tumours. APMIS. 1994; 102: 786-792.
48. Stewart LA. Chemotherapy in adult high-grade glioma:A systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet. 2002; 359: 1011-1018.
49. Tada M, Matsumoto R, Iggo RD, Onimaru R, Shirato H, Sawamura Y, Shinohe Y. Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res. 1998; 58: 1793-1797.
50. Waha A, Baumann A, Wolf HK, Fimmers R, Neumann J, Kindermann D, Astrahantseff K, Blumcke I, von Deimling A, Schlegel U. Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor- pathway in human astrocytic gliomas. J Neurosurg. 1996; 85: 634-641.
51. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MT Jr, Mealey J Jr et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J Neurosurg. 1978; 49: 333-343.
52. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980; 303: 1323-1329.
53. Wang Y, Zhu S, Lu KV et al. EGFRvIII sensitizes PTEN-expressing glioblastoma cells to erlotinib: A critical role for PI3K pathway modulation. Proc Amer Assoc Cancer Res, 2005; 46: Abstract #3409.
54. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpressions of the EGF receptor and p53 mutation are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 1996; 6: 217-223.
55. Zhou YH, Tan F, Hess KR, Yung WKA. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas. relationship to tumor grade and survival. Clinical Cancer Research. 2003; 9: 3369-3375.
56. Zhu A, Shaeffer J, Leslie S, Kolm P, El-Mahdi AM. Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. Int J Radiat Oncol Biol Phys. 1996; 34: 809-815.